Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 17 results.
User Information
Export Records
  1. 1.   Plasma and CNS pharmacokinetics of O(4)-benzylfolic acid (O(4)BF) and metabolite in a non-human primate model
  2. Chuk, M. K.; Cole, D. E.; McCully, C.; Loktionova, N. A.; Pegg, A. E.; Parker, R. J.; Pauly, G.; Widemann, B. C.; Balis, F. M.; Fox, E.
  3. Cancer Chemotherapy and Pharmacology. 2011, Jun; 67(6): 1291-1297.
  1. 2.   Genetically modified dendritic cells in cancer immunotherapy: a better tomorrow?
  2. Shurin, M. R.; Gregory, M.; Morris, J. C.; Malyguine, A. M.
  3. Expert Opinion on Biological Therapy. 2010, Nov; 10(11): 1539-1553.
  1. 3.   Aprotease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity
  2. Weldon, J. E.; Xiang, L. M.; Chertov, O.; Margulies, I.; Kreitman, R. J.; FitzGerald, D. J.; Pastan, I.
  3. Blood. 2009 113(16): 3792-3800.
  1. 4.   Immunotherapy of cancer by IL-12-based cytokine combinations
  2. Weiss, J. M.; Subleski, J. J.; Wigginton, J. M.; Wiltrout, R. H.
  3. Expert Opinion on Biological Therapy. 2007, Nov; 7(11): 1705-1721.
  1. 5.   Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients
  2. Onda, M.; Nagata, S.; FitzGerald, D. J.; Beers, R.; Fisher, R. J.; Vincent, J. J.; Lee, B.; Nakamura, M.; Hwang, J. L.; Kreitman, R. J.; Hassan, R.; Pastan, I.
  3. Journal of Immunology. 2006, Dec; 177(12): 8822-8834.
  1. 6.   Anti-HIV-1 immunotoxin 3B3(Fv)-PE38: enhanced potency against clinical isolates in human PBMCs and macrophages, and negligible hepatotoxicity in macaques
  2. Kennedy, P. E.; Bera, T. K.; Wang, Q. C.; Gallo, M.; Wagner, W.; Lewis, M. G.; Berger, E. A.; Pastan, I.
  3. Journal of Leukocyte Biology. 2006, Nov; 80(5): 1175-1182.
  1. 7.   Proteasome inhibition to maximize the apoptotic potential of cytokine therapy for murine neuroblastoma tumors
  2. Khan, T.; Stauffer, J. K.; Williams, R.; Hixon, J. A.; Salcedo, R.; Lincoln, E.; Back, T. C.; Powell, D.; Lockett, S.; Arnold, A. C.; Sayers, T. J.; Wigginton, J. M.
  3. Journal of Immunology. 2006, MAY 15; 176(10): 6302-6312.
  1. 8.   Therapeutic modulation of Akt activity and antitumor efficacy of interleukin-12 against orthotopic murine neuroblastoma
  2. Khan, T.; Hixon, J. A.; Stauffer, J. K.; Lincoln, E.; Back, T. C.; Brenner, J.; Lockett, S.; Nagashima, K.; Powell, D.; Wigginton, J. M.
  3. Journal of the National Cancer Institute. 2006, FEB 1; 98(3): 190-202.
  1. 9.   Role of glutathione and nucleotide excision repair in modulation of cisplatin activity with O-6-benzylguanine
  2. Fishel, M. L.; Ganicsik, M. P.; Delaney, S. M.; Zuhowski, E. G.; Maher, V. M.; Karrison, T.; Moschel, R. C.; Egorin, M. J.; Dolan, M. E.
  3. Cancer Chemotherapy and Pharmacology. 2005, APR; 55(4): 333-342.
  1. 10.   Effect of cell cycle inhibition on cisplatin-induced cytotoxicity
  2. Fishel, M. L.; Newell, D. R.; Griffin, R. J.; Davison, R.; Wang, L. Z.; Curtin, N. J.; Zuhowski, E. G.; Kasza, K.; Egorin, M. J.; Moschel, R. C.; Dolan, M. E.
  3. Journal of Pharmacology and Experimental Therapeutics. 2005, JAN; 312(1): 206-213.
  1. 11.   IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: Role for CD8(+) T cells
  2. Salcedo, R.; Stauffer, J. K.; Lincoln, E.; Back, T. C.; Hixon, J. A.; Hahn, C.; Shafer-Weaver, K.; Malyguine, A.; Kastelein, R.; Wigginton, J. M.
  3. Journal of Immunology. 2004, DEC 15; 173(12): 7170-7182.
  1. 12.   Vaccination of women with metastatic breast cancer, using a costimulatory gene (CD80)-modified, HLA-A2-matched, allogeneic, breast cancer cell line: Clinical and immunological results
  2. Dols, A.; Smith, J. W.; Meijer, S. L.; Fox, B. A.; Hu, H. M.; Walker, E.; Rosenheim, S.; Moudgil, T.; Doran, T.; Wood, W.; Seligman, M.; Alvord, W. G.; Schoof, D.; Urba, W. J.
  3. Human Gene Therapy. 2003 14(11): 1117-1123.
  1. 13.   Enhancement of platinum-induced cytotoxicity by O-6- Benzylguanine
  2. Fishel, M. L.; Delaney, S. M.; Friesen, L. D.; Hansen, R. J.; Zuhowski, E. G.; Moschel, R. C.; Egorin, M. J.; Dolan, M. E.
  3. Molecular Cancer Therapeutics. 2003 2(7): 633-640.
  1. 14.   Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity
  2. Greiner, J. W.; Zeytin, H.; Anver, M. R.; Schlom, J.
  3. Cancer Research. 2002 62(23): 6944-6951.
  1. 15.   Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells
  2. Conze, D.; Weiss, L.; Regen, P. S.; Bhushan, A.; Weaver, D.; Johnson, P.; Rincon, M.
  3. Cancer Research. 2001 61(24): 8851-8858.
  1. 16.   Abrogation of the hematological and biological activities of the interleukin-3/granulocyte-macrophage colony-stimulating factor fusion protein PIXY321 by neutralizing anti-PIXY321 antibodies in cancer patients receiving high-dose carboplatin
  2. Miller, L. L.; Korn, E. L.; Stevens, D. S.; Janik, J. E.; Gause, B. L.; Kopp, W. C.; Holmlund, J. T.; Curti, B. D.; Sznol, M.; Smith, J. W.; Urba, W. J.; Donegan, S. E.; Watson, T. M.; Longo, D. L.
  3. Blood. 1999 93(10): 3250-3258.
  1. 17.   Synthesis and biological evaluation of benzocyclooctene-based and indene-based anticancer agents that function as inhibitors of tubulin polymerization
  2. Herdman, Christine A.; Strecker, Tracy E.; Tanpure, Rajendra P.; Chen, Zhi; Winters, Alex; Gerberich, Jeni; Liu, Li; Hamel, Ernest; Mason, Ralph P.; Chaplin, David J.; Trawick, Mary Lynn; Pinney, Kevin G.
  3. MEDCHEMCOMM. 2016 7(12): 2418-2427.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel